Patients with stage D heart failure (HF) have limited life-prolonging therapeutic options other than left ventricular assist devices (LVADs) and cardiac transplant.
1 As few patients can undergo transplant and outcomes with mechanical circulatory support have greatly improved, the population of patients with durable LVADs is increasing.
2 However, data on the use of pharmacotherapy beyond the use of anticoagulation to prevent thrombotic events are limited. Specifically, little is known about the association of neurohormonal blockade (NHB) with clinical outcomes in patients with LVADs.